Medtronic Pacemaker Recall Issued for Consulta and Syncra Implants

|

Medtronic has sent a letter to hospitals and health care providers about potential manufacturing problems with Consulta and Syncra implantable pacemakers.

The Medtronic Consulta and Syncra pacemaker recall was announced by the FDA on July 16, after an urgent field safety notice (PDF) was sent out by Medtronic last month.

The devices, known as cardiac resynchronization therapy pacemakers (CRT-Ps) may have certain manufacturing defects, which could pose a potential risk for patients. However, there have been no injuries or adverse events reported in connection to the problem, according to the FDA.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

“This issue was identified as a result of an internal investigation that indicated a recent trend of increasing manufacturing rejects related to the weld of the connector bracket,” Medtronic wrote to its customers. “An out-of-specification weld could result in a loss of device hermeticity and compromise device functionality.”

The recall only affects non-implanted Consulta CRT-P Model C4TR01 and C3TR01 (not approved for use in the U.S.) and Syncra CRT-P Model C2TR01 devices manufactured between April 1 and May 13, 2013. The company made no recommendations regarding devices that have already been implanted in patients. The FDA announcement includes a full list of serial numbers of affected devices.

Medtronic is calling for the non-implanted devices affected by the recall to be returned for inspection. The company also wants implanted devices affected by the recall registered by calling the Medtronic Patient Registration Department at (800) 848-9300. Customers with questions can also call (763) 526-6000.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Image Credit: |



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A new lawsuit against Roblox alleges that the platform’s inadequate safety measures enabled multiple sexual predators to exploit a five-year-old girl.
Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.